Drug Fever

Dominique Vodovar, Christine LeBeller, Bruno Mégarbane, Agnes Lillo-Le-Louet and Thomas Hanslik ()
Additional contact information
Dominique Vodovar: Ambroise Paré Hospital
Christine LeBeller: European Georges Pompidou Hospital
Bruno Mégarbane: Lariboisière Hospital
Agnes Lillo-Le-Louet: European Georges Pompidou Hospital
Thomas Hanslik: Ambroise Paré Hospital

Drug Safety, 2012, vol. 35, issue 9, No 6, 759-767

Abstract: Abstract Background: Although known as a rare adverse drug reaction (ADR), drug fever (DF) remains an important issue in medicine, with the risk of leading to inappropriate and potentially harmful diagnostic and therapeutic interventions. Only sparse data regarding DF have been published. Objective: The aim of the study was to investigate which drugs were associated with DF, and report outcomes. Methods: Cases of DF without skin reactions were selected from all ADRs reported from 1986 to 2007 in the French National Pharmacovigilance Database. Drugs potentially responsible for DF were assessed using a qualitative case-by-case analysis (Naranjo’s criteria) and quantitative measurement (proportional reporting ratio [PRR]). A drug was implicated as the cause of DF when the following criteria were validated: three or more cases and PRR of at least two with a Chi-squared value of at least four. Results: A total of 167 DF cases involving 115 drugs were eligible. Based on the PRR, 22 drugs were significantly associated with DF. Antibacterials represented the most frequently reported drugs, including amikacin (PRR 39.6 [95% CI 23.6, 69.0], oxacillin (9.1 [3.6, 23.4]), cefotaxime (5.5 [2.0, 15.3]), ceftriaxone (5.4 [2.6, 11.3]), rifampicin (4.0 [1.8, 9.2]), vancomycin (4.0 [1.4, 11.5]), ciprofloxacin (3.1 [1.2, 8.0]), isoniazid (3.9 [1.4, 11.4]), pristinamycin (3.1 [1.0, 9.1]) and cotrimoxazole (2.6 [1.2, 5.8]). Median time [interquartile range] from drug administration to fever onset was 2 days [1.0–10.5]. A diagnosis of DF was made following cessation of the suspected drugs (3 days [1.0–11.5] after fever onset. Drug rechallenge was performed (38.0%), resulting in recurrence of DF in all cases. DF resulted in life-threatening events (0.6%), hospitalization or prolonged hospital stay (24.5%) and persistent disability (0.6%). Final outcome was favourable in 96.9% of cases after drug discontinuation. Conclusion: Diagnosing DF is challenging. Based on this large series, antibacterials remain the major class of drugs responsible for DF.

Keywords: Adverse Drug Reaction; Malignant Hyperthermia; Drug Discontinuation; Adverse Drug Reaction Report; Suspected Drug (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/BF03261972 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:35:y:2012:i:9:d:10.1007_bf03261972

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/BF03261972

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().